ISRG Stock Recent News

Intuitive Surgical's da Vinci system is driving strong global growth, with 17% YoY procedure growth and expanding adoption across hospitals and specialties. Recurring revenue streams from system sales, procedures, and services support robust financials, including 21% YoY revenue growth and 68% gross margins. The company's expanding installed base and accelerating procedure growth position it for continued earnings stability and long-term shareholder returns.

Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.

Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.

If you're a growth-oriented investor like me, you've probably seen your portfolio experience its fair share of ups and downs the last few years. While the market has rebounded to new heights and many growth businesses have recovered spectacularly, results have varied by individual stock.

Investing in stocks for the long term can help you build a profitable portfolio that enables you to meet your personal financial goals. Not every stock will be a winner, and no investor is perfect.

Cathie Wood is built for rallying markets. The co-founder, CEO, and chief investment officer of Ark Invest is crushing the market this year, proving that she can catch 2020 in a bottle again.

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.

Intuitive Surgical (ISRG 1.46%) is one of the best success stories you'll find in the healthcare sector. The company has helped patients worldwide as a pioneer in robotic-assisted surgery, and its business success has driven the stock to returns of over 25,000% since its initial public offering (IPO) in 2000.